Genmab A (GMAB) Cash & Equivalents (2018 - 2026)

Genmab A has reported Cash & Equivalents for 7 years, with the latest figure at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 10.22% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 10.22% YoY), and the FY2025 full-year result was $1.7 billion, up 24.28% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.5 billion, down from $1.7 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $2.2 billion in Q4 2023, with the low at $952.0 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $1.7 billion across 4 years, with a median of $1.6 billion in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 37.39% — and 2025, when it soared 84.98%.
• Genmab A's Cash & Equivalents stood at $2.2 billion in 2023, then tumbled by 37.39% to $1.4 billion in 2024, then advanced by 24.28% to $1.7 billion in 2025, then decreased by 11.31% to $1.5 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.5 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.